At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 44 enrolled
Drug / intervention
MM-121drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I and Pharmocologic Study of MM-121 in Patients With Refractory Advanced Solid Tumors
In Brief
A Phase 1 clinical trial evaluating MM-121 for Advanced Solid Tumors. Completed, enrolled 44 participants across 3 sites.
Detailed Summary
This study was a Phase 1 and pharmacologic open-labeled dose-escalation trial using a "3+3" design to determine maximum tolerated dose/recommended Phase 2 dose.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Solid Tumors
CountriesUnited States
CollaboratorsSanofi
Timeline
Phase 1CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2008
First PostedAug 2008
Primary CompletionMay 2010
Study CompletionSep 2013
TodayJul 2026
First PostedAug 14, 2008
Enrollment StartJul 1, 2008
Primary CompletionMay 1, 2010
Study CompletionSep 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 17.9 years ago
Interventions
MM-121drug
Dose escalation Frequency - once weekly